←Geriatric Patients
Study register · detail Narrative Review · Geriatric Patients · 2023

Medical Cannabis Use and Its Impact on Health Among Older Adults: Recent Research Findings and Future Directions

Wang et al. ·Current Addiction Reports
No direction reported 10 citations
SampleNarrative Review
DesignNarrative Review
Summary

Narrative review on medical cannabis in older adults; potential therapeutic effects for chronic pain, insomnia, anxiety/depression, dementia, nausea/vomiting, but evidence inconsistent and mostly based on self-reports/uncontrolled studies. Cannabis generally well tolerated, but neurocognitive, psychiatric and cardiovascular risks reported in limited studies. Call for more rigorous research on safety and efficacy.

SummaryNarrative review on medical cannabis in older adults (≥50 years). Summary of current literature (2018–2023) on barriers, potential benefits (chronic pain, sleep disorders, dementia, nausea) and risks (neurocognitive, cardiovascular effects). Evidence to date inconsistent, predominantly from observational studies; only 8 small RCTs with <250 older participants. Call for rigorous controlled studies with real-world dispensary products.
Quality profile
Sample size —
Blinding —
Effect size —
Citations / year ★★★★★
Authors
Wang Y, Robinson KR, Fechtel H, Hartog A
DOI 10.1007/s40429-023-00519-x↗
Design: Narrative Review
Share
Indication
Further studies on Geriatric Patients
All studies →
A Ceolin et al. · 2024 · The journal of nutrition, health & aging
4 citations
The potential of cannabinoids in managing cancer-related anorexia in older adults: a systematic review of the literature.
Mixed Systematic Review

Systematische Review zu Cannabinoiden bei Tumor-assoziierter Anorexie älterer Erwachsener; k=6 Studien (5 RCTs, 1 prospektive Studie), n=869 Teilnehmende (2002-2019). Megestrol 800 mg/d wirksamer als Dronabinol 2,5 mg 2×/d für Appetit. Nabilone 1,0 mg/d über 8 Wochen: signifikanter Anstieg Kalorienaufnahme und Kohlenhydratkonsum vs. Placebo. THC 5-10 mg/d: Gewichtszunahme ≥10% bei 17,6% der Patienten, verbesserte Chemosensorik und Appetit bei THC 2,5 mg vs. Placebo. Keine schwerwiegenden Nebenwirkungen berichtet.

10.1016/j.jnha.2024.100299 View study →
A Rosenberg et al. · 2026 · The American journal of geriatric psychiatry
3 citations
A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease.
Clear benefit RCT

n=75 Alzheimer-Patienten mit Agitation (NPI-C A/A ≥4), randomisiert doppelblind placebokontrolliert; Dronabinol (THC) bis 10 mg/Tag vs. Placebo über 3 Wochen (5 akademische Zentren, USA). Pittsburgh Agitation Scale (PAS): signifikant stärkere Abnahme unter Dronabinol (Differenz –0,74/Woche, SE 0,3, p=0,015, Effektgröße 0,53). NPI-C A/A Differenz –1,26 (SE 0,67, p=0,094). Keine erhöhte Intoxikation; Somnolenz als einzige signifikante Nebenwirkung. Adjunktives Dronabinol sicher und klinisch wirksam bei Agitation bei Alzheimer-Demenz.

10.1016/j.jagp.2025.10.011 View study →
A Pisani et al. · 2021 · Drugs & Aging
19 citations
Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies.
Mixed Systematische Review und Meta-Analyse

SR und Meta-Analyse (k=38 Studien, N=2.341, Durchschnittsalter 63,2 Jahre); THC: Inzidenzrate (IR) aller UAW 122,18 (95%-KI 38,23–253,56), schwere UAW IR=0; CBD: IR aller UAW 111,91 (95%-KI 1,24–495,93), keine schweren UAW; THC:CBD-Kombination: schwere UAW IR 21,32 (95%-KI 0,18–93,26) — Cannabinoide insgesamt gut verträglich bei Erwachsenen >50 Jahre.

10.1007/s40266-021-00882-2 View study →

The impediment to action advances action. — Marcus Aurelius